Rituximab associated with lower drug discontinuation and disease relapse rates in multiple sclerosis
Rituximab was associated with lower discontinuation rates as compared to other disease-modifying treatments in newly diagnosed patients with relapsing-remitting multiple sclerosis.
The researchers found that the mean change in the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale was 0.37, 0.61, and 0.41 for the 60- and 30-mg idalopirdine groups and the placebo group, respectively.
Gocovri is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Although the research found opioid use to have a favorable risk-benefit ratio, other avenues of treatment should be considered before opioid prescription including addressing iron stores and combination therapy.
Of the 494 patients, 43.5% received an injectable DMT, 17.4% dimethyl fumarate, 3.4% fingolimod, 10.1% natalizumab, 24.3% rituximab, and 1.2% other DMT.
Children exposed to antiepileptic drugs (AEDs) in utero may have a reduced risk of autistic traits with periconceptional folic acid supplementation and folate status
Angelman syndrome affects approximately 1 in 12,000 to 20,000 in the U.S. and symptoms include delayed development, intellectual disability, and seizures.
Researchers from the University of Minnesota in Minneapolis reviewed data from 32 trials to examine the effectiveness of physical activity interventions in slowing cognitive decline and delaying the onset of cognitive impairment and dementia.
The FDA has granted Breakthrough Therapy designation for fingolimod for the treatment of children and adolescents 10 years of age or older with relapsing multiple sclerosis (MS).
The FDA's approval was based on results from the 'Intrepid' study, the first multi-center, prospective, double-blind, randomized sham-controlled study of DBS for Parkinson's Disease in the U.S.
Within 4 months of enzalutamide initiation, four patients (1.1%) had at least one confirmed seizure; three additional patients (0.8%) experienced a seizure within four months following the 4-month study period.
The researchers found that having dietary quality scores in the highest versus the lowest quintile correlated with lower levels of disability.
After adjusting for gender, age, education level, baseline neurocognitive performance, and others, the authors reported gadolinium exposure was not a significant predictor of cognitive decline, dementia, diminished neuropsychological performance or diminished motor performance
The researchers found that the ACB showed the strongest and most consistent dose-response relationships with risks of all four adverse outcomes compared with ARS and DBI-Ach, especially among those aged 65 to 84 years.
There was no difference in the composite functional measure (walking control, balance, manual dexterity, postvoid residual urine volume, and visual acuity) between the PTA and sham groups (41.7 vs. 48.7%; odds ratio, 0.75; 95% confidence interval, 0.34 to 1.68; P=0.49).
Treatments for cervical dystonia include oral medications, botulinum toxin injections, surgery, and complementary therapies.
Dependent on further input from the Data Safety Monitoring Board (DSMB) and the Food and Drug Administration (FDA), the Company stated that they intend on moving forward with the study and expect to report results in the first quarter of 2018.
The researchers found that the mass spectrometry-derived Aβ42 values showed higher correlations with the modified Aβ42-INNOTEST, Aβ42-FL, Aβ42-EI, and Aβ42-MSD assays versus the classic Aβ42-INNOTEST assay.
Data were included for 262 patients with a history of WNV enrolled in a longitudinal cohort from 2002 to 2012; 117 patients underwent neurologic and neurocognitive evaluations.